Huons Co., Ltd. (243070.KQ)
KRW 28400.0
(1.79%)
KRW 28400.0
(1.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 206.87 Billion KRW | 11.76% |
| 2022 | 185.1 Billion KRW | 11.33% |
| 2021 | 166.26 Billion KRW | -3.89% |
| 2020 | 172.99 Billion KRW | 69.41% |
| 2019 | 102.12 Billion KRW | 22.02% |
| 2018 | 83.68 Billion KRW | -8.75% |
| 2017 | 91.71 Billion KRW | 9.7% |
| 2016 | 83.6 Billion KRW | 0.0% |
| 2014 | 66.13 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 206.5 Billion KRW | -0.18% |
| 2024 Q2 | 222.34 Billion KRW | 7.67% |
| 2023 Q4 | 206.87 Billion KRW | 17.21% |
| 2023 FY | 206.87 Billion KRW | 11.76% |
| 2023 Q1 | 174.71 Billion KRW | -5.62% |
| 2023 Q2 | 163.31 Billion KRW | -6.52% |
| 2023 Q3 | 176.5 Billion KRW | 8.07% |
| 2022 Q2 | 191.05 Billion KRW | 13.72% |
| 2022 Q1 | 168.01 Billion KRW | 1.05% |
| 2022 FY | 185.1 Billion KRW | 11.33% |
| 2022 Q4 | 185.1 Billion KRW | 0.45% |
| 2022 Q3 | 184.28 Billion KRW | -3.55% |
| 2021 Q2 | 151.33 Billion KRW | -17.85% |
| 2021 Q4 | 166.26 Billion KRW | 3.38% |
| 2021 Q1 | 184.2 Billion KRW | 6.48% |
| 2021 FY | 166.26 Billion KRW | -3.89% |
| 2021 Q3 | 160.83 Billion KRW | 6.28% |
| 2020 FY | 172.99 Billion KRW | 69.41% |
| 2020 Q4 | 172.99 Billion KRW | 30.64% |
| 2020 Q3 | 132.42 Billion KRW | -1.73% |
| 2020 Q2 | 134.75 Billion KRW | 20.41% |
| 2020 Q1 | 111.91 Billion KRW | 9.59% |
| 2019 FY | 102.12 Billion KRW | 22.02% |
| 2019 Q1 | 89.92 Billion KRW | 7.46% |
| 2019 Q4 | 102.12 Billion KRW | 11.15% |
| 2019 Q3 | 91.87 Billion KRW | 6.79% |
| 2019 Q2 | 86.03 Billion KRW | -4.32% |
| 2018 FY | 83.68 Billion KRW | -8.75% |
| 2018 Q3 | 68.52 Billion KRW | -4.17% |
| 2018 Q2 | 71.51 Billion KRW | -8.28% |
| 2018 Q4 | 83.68 Billion KRW | 22.12% |
| 2018 Q1 | 77.96 Billion KRW | -14.99% |
| 2017 Q2 | 81.15 Billion KRW | -4.74% |
| 2017 Q4 | 91.71 Billion KRW | 8.32% |
| 2017 FY | 91.71 Billion KRW | 9.7% |
| 2017 Q1 | 85.19 Billion KRW | 1.9% |
| 2017 Q3 | 84.66 Billion KRW | 4.33% |
| 2016 Q3 | 81.87 Billion KRW | 0.0% |
| 2016 Q4 | 83.6 Billion KRW | 2.11% |
| 2016 FY | 83.6 Billion KRW | 0.0% |
| 2014 FY | 66.13 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 53.19 Billion KRW | -288.873% |
| CMG Pharmaceutical Co., Ltd. | 40.02 Billion KRW | -416.797% |
| Celltrion Pharm, Inc. | 264.97 Billion KRW | 21.928% |
| Huons Global Co., Ltd. | 407.28 Billion KRW | 49.207% |
| DongKook Pharmaceutical Co., Ltd. | 263.36 Billion KRW | 21.449% |
| Enzychem Lifesciences Corporation | 16.91 Billion KRW | -1122.738% |
| Humedix Co., Ltd. | 21.91 Billion KRW | -843.996% |
| Boditech Med Inc. | 30.48 Billion KRW | -578.604% |
| EuBiologics Co., Ltd. | 67.82 Billion KRW | -205.014% |
| FutureChem Co.,Ltd | 8.91 Billion KRW | -2219.517% |
| BNC Korea Co., Ltd. | 21.94 Billion KRW | -842.65% |
| AptaBio Therapeutics Inc. | 38.19 Billion KRW | -441.668% |